Nuevos tratamientos están dando razones para tener esperanza frente al cáncer de páncreas. Acompáñenos en el seminario web Let’s Learn con el Dr. Arturo Loaiza-Bonilla (@DrArturoAI) y Catalina Fandino.
Jueves 29 de oct., 2 p. m. ET 💜
Regístrese: https://t.co/P5rLGsRAHb
When a loved one is being treated for pancreatic cancer, caregivers become at-home nurses. Marci Andrejko provides some best practices. https://t.co/roySrBVeJc
Nuevos tratamientos están dando razones para tener esperanza frente al cáncer de páncreas. Acompáñenos en el seminario web Let’s Learn con el Dr. Arturo Loaiza-Bonilla (@DrArturoAI) y Catalina Fandino.
Jueves 29 de oct., 2 p. m. ET 💜
Regístrese: https://t.co/P5rLGsRAHb
Honored to have #Atebimetinib on the cover of Cancer Research, and grateful to the entire @Immuneering $IMRX team for years of persistent, data-driven hard work on behalf of cancer patients ... full speed ahead!
Excellent review in @CCR_AACR by @Dr_R_Kurzrock on an important non-RAS target in oncology, Claudin 18.2. Cancer adapts fast, so alternating between non-RAS and RAS targets in sequence may become an important strategy for maximizing survival. Yet non-RAS targets tend to fly under the radar these days. In pancreatic cancer in particular, Claudin 18.2 is important (for ~30% of patients); so is MEK (for almost all patients, and our focus at @Immuneering $IMRX with #atebimetinib), PRMT5 (for patients with MTAP deletions), CD73, GSK-3beta, and others. Have a non-RAS target in pancreatic cancer you think deserves more attention? Please add to the comments …
@PanCAN@letswinpc #PancreaticCancer #PDAC
My posts contain forward looking statements about Immuneering: please refer to our SEC filings for more information.
🇪🇺Europe is stepping up in the treatment of
#PancreaticCancer with the first Multidisciplinary #Guidelines and the #PALACROS project 🔥
🤝Involving over 30 societies and patient organizations, 15 countries and 60+ centers across Europe
🙌Thanks to @my_ueg (14,000+ attendees!) for highlighting these developments!
🔗#PALACROS including the #PREOPANC4 RCT #PULSE and #PIVOTAL trials: https://t.co/i0rELtbABf
🔗#Guidelines protocol: https://t.co/i0rELtbABf
ASCO Leads: Latin America applications open! Apply by 10/26 to join us in Costa Rica Feb. 11-12, 2027, for leadership training & premier networking. Designed for mid-career ASCO Members currently practicing oncology in the Latin America region. Learn more: https://t.co/ZLjAy6KFKp
🚨⭐️⭐️⭐️📍📌 Mark your calendars 📅 @myESMO MADRID
📍Saturday, Oct 24 · 14:45–15:45 · Santander Auditorium, Hall 10
👉Delighted to be delivering a lecture: “Drugging the Undruggables: The Next Wave of Targeted Therapies #PrecisionOncology.” 🧬🎯beyond KRAS, P53, MYC & much much more @Annals_Oncology #ESMOAmbassadors
👉Session: “YO Lecture: What to expect from precision medicine in the next decade” #ESMO26 #PrecisionOncology #TargetedTherapy
👉I’ll be presenting the latest+ greatest in the field, and looking for what comes next.
👉👉👉PLEASE ATTEND + Come with questions @OncoAlert@Aiims1742@BalazsHalmosMD@oncologiaroma@PTarantinoMD@curijoey@FAndreMD@CharlesSwanton
Session LINK: https://t.co/qJmEC1IA8Q
Elvin Howard Jr of the Elvin Howard Sr. Pancreatic Cancer Advocacy Foundation joins @talk1073@JaguarJournal_ host @_WHEreIsPERRY to promote pancreatic cancer awareness as well as the upcoming 5K run/1mile walk
🔽Learn More By Clicking The Link Below🔽
https://t.co/Ix4F5WDgRv
How can you tell if a scientific study is good? Learn what to look for in reliable studies and whether a trial may be right for you. https://t.co/dH4G0PHPfK
A tumor board brings together experts in different treatment fields to discuss your case and help direct your pancreatic cancer treatment. https://t.co/tjAFd1KQUS
Do you want to understand more about how your doctor chooses your treatments? Learn about the standard of care for pancreatic cancer. https://t.co/hDSmYmFv0u
An oncology pharmacist plays an important role on a patient’s care team. Learn more from Dr. Tammy McClellan about what oncology pharmacists do. https://t.co/dqt49gGYw6
Pancreatic neuroendocrine tumor patient Burt Rosen uses artificial intelligence to help him understand medical data, and to make him laugh. https://t.co/nSknFJj390
Do you have questions about the newly approved drug Rasonque, generic name daraxonrasib? You can find answers to all your questions on this page from our partner, @letswinpc. https://t.co/NpHJKi5xss
We are saddened to share Dr. Rachna Shroff, a member of our Scientific Advisory Board, has passed away. A physician-scientist and tireless advocate for clinical trials, she made a lasting difference for people facing pancreatic cancer. Our 💜 is with her family and loved ones.